Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30848800 | 1.00 | EGFR (0.40) | EGFRPOLBTDP1L3MBTL1NOTUM | |
| SCHEMBL24826464 | 0.88 | EGFR (0.50) | EGFRPOLBTDP1L3MBTL1NOTUM | |
| SCHEMBL30848835 | 0.88 | EGFR (0.50) | EGFRPOLBTDP1L3MBTL1NOTUM | |
| SCHEMBL30848806 | 0.87 | EGFR (0.51) | EGFRNOTUM | |
| SCHEMBL24826754 | 0.87 | EGFR (0.40) | EGFRKDM4EMEN1KMT2A | |
| SCHEMBL30164940 | 0.87 | EGFR (0.40) | EGFRKDM4EMEN1KMT2A | |
| SCHEMBL24825129 | 0.87 | EGFR (0.51) | EGFRNOTUM | |
| SCHEMBL24826768 | 0.86 | EGFR (0.36) | EGFR | |
| SCHEMBL30164881 | 0.86 | EGFR (0.36) | EGFR | |
| SCHEMBL24826745 | 0.85 | EGFR (0.46) | EGFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117858872-A | Heterocyclic EGFR inhibitors for the treatment of cancer | 缆图药品公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2022271612-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |